While there is limited evidence supporting β2-MG as a standalone prognostic marker for pancreatic cancer, its combination with serological markers, such as high preoperative levels of serum tumor markers such as glycan carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and cancer antigen 125 (CA125), is associated with worse tumor differentiation and shorter overall survival. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.